Recce Pharmaceuticals (ASX:RCE) has secured human research ethics committee approval to allow up to 20 additional patients in its phase two clinical study to access Recce 327, a topical gel designed for diabetic foot infections (DFI), according to a Tuesday filing with the Australian bourse.
The study will run concurrently with Recce's phase three trial in Indonesia, which is expected to deliver results later in the year, with regulatory approval and commercial launch anticipated in the first half of 2026, the filing said.
Both studies aim to generate additional data to support future regulatory submissions, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.